AKT1 and cancer: The recognition of the PI3K/AKT/mTOR pathway as a key regulator of hypoxia‐induced EMT and drug resistance in various cancers underscores the importance of targeting this pathway to improve treatment outcomes and overcome therapeutic challenges.